UK government commits USD4.8M to scale MHRA’s “AI Airlock” regulatory sandbox

UK—The Medicines and Healthcare Products Regulatory Agency (MHRA) will now receive £1.2 million annually through 2029, bringing a total three-year increase of £3.6 million (US$4.8 million) from the Department of Health and Social Care (DHSC).

This multi-year commitment signals a major shift in how the government approaches AI healthcare innovation, replacing the constraints of year-to-year budgeting with sustained, long-term investment.

Expanding the AI Airlock programme

The funding will strengthen AI Airlock, the UK’s regulatory sandbox specifically designed to test artificial intelligence medical devices.

The programme, jointly operated by the MHRA, DHSC, NHS AI Team, and Team AB—a consortium of approved UK bodies—sits at the centre of the government’s broader healthcare transformation agenda.

It aligns with multiple strategic initiatives, including the Regulatory Action Plan, the AI Opportunities Action Plan, the 10-Year Health Plan, and the Life Sciences Sector Plan.

Since launching in 2024, AI Airlock has grown steadily, moving beyond its initial pilot phase to tackle increasingly complex regulatory questions.

The pilot phase uncovered critical challenges unique to artificial intelligence systems in medical settings.

Developers must now address AI-specific risks, such as minimising errors by anchoring model responses in validated clinical data.

Equally important, regulators discovered the need for continuous monitoring after products reach patients, ensuring performance remains consistent and healthcare professionals do not over-rely on algorithmic recommendations.

Current phase and future outlook

The programme’s current phase continues investigating how AI can support medical diagnostics, from rare disease detection to cancer screening.

Researchers are evaluating diverse technologies, including voice-enabled tools, large language models, and specialised diagnostic systems.

The MHRA has been publishing detailed reports and case studies to guide companies navigating this emerging regulatory landscape.

James Pound, executive director of innovation and compliance at the MHRA, described the funding decision as pivotal for advancing AI in healthcare.

He emphasised that the investment enables the regulator to scale operations and strengthen oversight capacity, ensuring AI-powered devices reach patients safely and efficiently while maintaining public confidence in regulatory standards.

Industry observers note that this commitment reflects growing recognition that AI medical devices require distinct regulatory frameworks.

Rather than forcing new technologies into traditional pathways, the UK is creating bespoke structures to evaluate their unique benefits and risks.

The MHRA expects findings from the current phase in mid-2026, which will inform the next generation of AI medical device approvals.

In February, the agency reported a record number of device trial approvals across the UK, demonstrating the regulator’s capacity to move innovative products through the system without compromising safety or effectiveness.